HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, reported financial and operational results for the quarter ended September 30, 2024. The company recorded a net loss of $13.8 million for the quarter, compared to a net loss of $19.1 million for the same period in 2023. The net loss per share, basic and diluted, was $1.10 for the quarter, an improvement from $1.73 in the previous year. Research and development expenses decreased to $15.6 million from $24.6 million year-on-year, reflecting a strategic refocus and workforce reductions. General and administrative expenses increased to $6.7 million from $4.9 million, due to higher personnel-related expenses and professional fees. The company's cash, cash equivalents, and restricted cash totaled $60.0 million as of September 30, 2024. HOOKIPA Pharma continues to advance its proprietary immuno-oncology...Show More

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, reported financial and operational results for the quarter ended September 30, 2024. The company recorded a net loss of $13.8 million for the quarter, compared to a net loss of $19.1 million for the same period in 2023. The net loss per share, basic and diluted, was $1.10 for the quarter, an improvement from $1.73 in the previous year. Research and development expenses decreased to $15.6 million from $24.6 million year-on-year, reflecting a strategic refocus and workforce reductions. General and administrative expenses increased to $6.7 million from $4.9 million, due to higher personnel-related expenses and professional fees. The company's cash, cash equivalents, and restricted cash totaled $60.0 million as of September 30, 2024. HOOKIPA Pharma continues to advance its proprietary immuno-oncology pipeline, with eseba-vec in clinical development for HPV16+ head and neck cancers and HB-700 for KRAS mutated cancers. The company has regained full control of the HB-700 program following Roche's termination of their collaboration agreement. HOOKIPA Pharma also collaborates with Gilead Sciences on developing functional cures for chronic Hepatitis B and HIV infections. The company's strategic focus includes the clinical development of eseba-vec and the Gilead-partnered infectious disease programs, while pausing other preclinical research activities. HOOKIPA Pharma is actively seeking additional funding and implementing cost-saving initiatives to support its operations.